Actionable news
0
All posts from Actionable news
Actionable news in LPCN: LIPOCINE INC,

FDA accepts Lipocine's NDA for lead product candidate LPCN 1021

The FDA accepts for review the New Drug Application (NDA) from Lipocine (NASDAQ:LPCN) seeking approval of lead product candidate LPCN 1021 for testosterone replacement therapy (TRT). The PDUFA date...


More